Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Management
    • Board
    • Company History
    • Vision
  • R&D
    • About Complement
    • About C5A
    • Technology
    • Pipeline
    • Clinical Development
      • Hidradenitis Suppurativa
        • Shine Study FAQ
      • ANCA-Associated Vasculitis
      • Pyoderma Gangraenosum
      • COVID-19
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions
      • Global Supply Manager (m/f/d) (up to 2)
      • Global Supply Coordinator, (m/f/d)
      • Qualified Person, (m/f/d)

Annual Meeting of the American Academy of Dermatology

  • Home
  • Investors
  • Events & Presentations
  • Meeting of American Academy of Dermatology

February 16 - 20, 2018 - Annual Meeting of the American Academy of Dermatology, San Diego, USA

Efficacy data on IFX-1 from the Phase 2a study in patients with severe Hidradenitis Suppurativa, not eligible for biological treatment or primary or secondary failure of biological treatment, have been accepted for the late breaking session.

Presenter:

Evangelos J. Giamarellos-Bourboulis, MD, PhD (ATTIKON University Hospital, Athens, Greece)

Date:

Saturday, Feb 17, 2018

Time:

2:40 pm PST

<< back to list

 image
Quick Links
  • Impressum
  • Privacy
  • Technology
  • Pipeline
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
  • Member area
Contact Jena

InflaRx N.V.
Winzerlaer Str. 2
07745 Jena

+49 (0)3641 508 180

info@inflarx.de

Contact Munich

InflaRx N.V.
Fraunhoferstraße 22
82152 Martinsried

+49 (0)89 414 189 78 00

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals